REG - Cambridge Cognition - Grant of Options
RNS Number : 9873DCambridge Cognition Holdings PLC02 November 2020Cambridge Cognition Holdings Plc
("Cambridge Cognition" or the "Company")
Grant of Options
Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, announces that on 2 November 2020, the Company granted options ("Options") over a total of 246,774 ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares") pursuant to the Company's EMI option scheme and the Company's unapproved option scheme.
Of these Options:
- 183,774 were granted to Persons Discharging Managerial Responsibilities ("PDMRs") on behalf of the Company;
Name
Role
Number of Options Granted
Total number of Options held following Grant
Total number of Ordinary Shares
Percentage of Current Issued Share Capital Held
Matthew Stork
Chief Executive Officer
103,774
693,061
125,000
0.40%
Fiona Cree
Chief Operating Officer
20,000
176,857
-
-
Richard Cooper
Chief Commercial Officer
60,000
171,786
-
-
- 63,000 were granted to other employees of the Company.
All the Options granted to PDMRs are exercisable at a price of 53 pence per Ordinary Share from three years following the date of award until the tenth anniversary of the date of award, subject to satisfying the following performance criteria:
o 50% of the Options granted will vest if the average closing mid-market price of an Ordinary Share for any three month period exceeds 90 pence, with the price on the last day of that period being at least 80 pence, and the last day of this period being no later than 31 October 2023; and
o 50% of the Options granted will vest if the average closing mid-market price of an Ordinary Share for any three month period exceeds 130 pence, with the price on the last day of that period being at least 115 pence, and the last day of this period being no later than 31 October 2023.
Of the options granted to other employees of the Company:
1. 60,000 are exercisable at a price of 53 pence per Ordinary Share from three years following the date of award until the tenth anniversary of the date of award, subject to satisfying the following performance criteria:
o 50% of the Options granted will vest if the average closing mid-market price of an Ordinary Share for any three month period exceeds 90 pence, with the price on the last day of that period being at least 80 pence, and the last day of this period being no later than 31 October 2023; and
o 50% of the Options granted will vest if the average closing mid-market price of an Ordinary Share for any three month period exceeds 130 pence, with the price on the last day of that period being at least 115 pence, and the last day of this period being no later than 31 October 2023.
2. The remaining 3,000 options are exercisable at a price of 1 pence per Ordinary Share from two years following the date of award until the tenth anniversary of the date of award. All of these Options are granted over shares already in issue and held by Cambridge Cognition Trustees Limited on behalf of the Employee Benefit Trust.
Following the grant of Options, the total number of Options outstanding over unissued Ordinary Shares is 2,476,636 representing approximately 7.95% of the Company's issued share capital.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1.
Details of the person discharging managerial responsibilities / person closely associated
a)
Names
Matthew Stork - Chief Executive Officer
Fiona Cree - Chief Operating Officer
Richard Cooper - Chief Commercial Officer
2.
Reason for the Notification
a)
Position/status
See 1(a) above for positions - all classified as PDMRs of the Company
b)
Initial notification/ Amendment
Initial Notification
3.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Cambridge Cognition Holdings Plc
b)
LEI
213800SZKDIN122EPA96
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the Financial instrument, type of instrument
In each case, the grant of Options over Ordinary Shares on 2 November 2020
Identification code
GB00B8DV9647
b)
Nature of the transaction
Grant of Options over Ordinary Shares
c)
Price(s) and volume(s)
Price: n/a
Volumes:
Matthew Stork - 103,774 Options
Fiona Cree - 20,000 options
Richard Cooper - 60,000 Options
d)
Aggregated information:
· Aggregated volume
· Price
n/a
e)
Date of the transaction
2 November 2020
f)
Place of the transaction
Outside a trading venue
The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014
Enquiries
Cambridge Cognition Holdings PLC
Matthew Stork, Chief Executive Officer
Nick Walters, Chief Financial Officer
Tel: 01223 810 700
finnCap Ltd (NOMAD and Joint Broker)
Tel: 020 7220 0500
Geoff Nash / Simon Hicks
(Corporate Finance)
Alice Lane/ Manasa Patil
(Corporate Broking)
Dowgate Capital Limited (Joint Broker)
David Poutney/ James Serjeant
Tel: 020 3903 7715
(Corporate Broking)
IFC Advisory Limited (Financial PR and IR)
Tel: 020 3934 6630
Tim Metcalfe/ Graham Herring/ Zach Cohen
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDDSHZLLFBBFLEFBL
Recent news on Cambridge Cognition Holdings
See all newsREG - Cambridge Cognition - Preliminary Results, Trading Update & Board Change
AnnouncementREG - Cambridge Cognition - Notice of Results
AnnouncementREG - Cambridge Cognition - COG spin-out Monument Therapeutics accesses £1.5m
AnnouncementREG - Cambridge Cognition - Total Voting Rights and Block Listing Return
AnnouncementREG - Cambridge Cognition - Formation of new Scientific Advisory Board
Announcement